Latest Breaking News On - Kynos therapeutics ltd - Page 1 : comparemela.com

Kynos Therapeutics announces positive top-line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement

Kynos Therapeutics announces positive top-line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomCity ofSue charlesJonathan savidgeKynos therapeutics ltdUniversity of edinburghIp groupTherapeutics ltdInnovate united kingdomKynos therapeuticsEpidarex capitalScottish enterpriseInnovate united

IP : Kynos Therapeutics announces positive top line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement

22 Apr 2024 Edinburgh UK, 22 April 2024 - Kynos Therapeutics Ltd, a clinical stage biotechnology company developing first-in-class small molecule kynurenine.

United kingdomJonathan savidgeKynos therapeutics ltdTherapeutics ltdInnovate united kingdom

Kynos Therapeutics announces a first-in-human Phase I study of its novel small molecule KMO inhibitor, KNS366, is underway

Kynos Therapeutics announces a first-in-human Phase I study of its novel small molecule KMO inhibitor, KNS366, is underwayEdinburgh UK, 18 May 2023 - Kynos Therapeutics Ltd, a biotechnology company developing a portfolio of first in class kynurenine 3-monooxygenase (KMO) inhibitors, today announces that dosing is un.

United kingdomJonathan savidgeKynos therapeutics ltdKynos therapeuticsTherapeutics ltdInnovate united kingdom

Kynos Therapeutics Emerges from Stealth with £9 Million Financing and Phase 1-ready KMO Inhibitor

Spin-out from the University of Edinburgh commercialising a decade of drug discovery research on kynurenine 3-monooxygenase (KMO), a pivotal enzyme in the.

United kingdomCity ofSam williamsElizabeth roperTassos konstantinouSue charlesScott websterIp group and scottish enterpriseCentre for cardiovascular scienceMain market of the london stock exchangeUniversity of edinburghPartner of life sciencesKynos therapeutics ltdIp groupUniversity of edinburgh centre for inflammation researchLife sciences